Table 1 Patient characteristics. *P<0.05
Patient characteristics | CBDCA + GEM (n = 65) | CDDP + VNR (n = 17) | P |
|---|---|---|---|
Median age, years (range) | 66 (43–79) | 59 (33–70) | 0.004* |
Gender (%) | Â | Â | 0.239 |
 Male | 51 (78.4) | 11 (64.7) |  |
 Female | 14 (21.5) | 6( 35.2) |  |
Surgical procedure (%) | Â | Â | 0.874 |
 Lobectomy | 61 (93.8) | 16 (94.1) |  |
 Pneumonectomy | 4 (6.1) | 1 (5.8) |  |
ECOG performance status (%) | Â | 0.002* | |
 0 | 36 (55.3) | 17 (100) |  |
 1 | 27 (41.5) | 0 |  |
 2 | 2 (3.0) | 0 |  |
Pathological stage (%) | Â | Â | 0.532 |
 IB | 3 (4.6) | 0 |  |
 IIA | 3( 4.6) | 1 (5.8) |  |
 IIB | 27 (41.5) | 4 (23.5) |  |
 IIIA | 22 (33.8) | 8 (47.0) |  |
 IIIB | 10 (15.3) | 4 (23.5) |  |
Histology (%) | Â | Â | 0.185 |
 Adenocarcinoma | 44 (67.6) | 16 (94.1) |  |
 Squamous cell carcinoma | 19 (29.2) | 1( 5.8) |  |
 Large cell carcinoma | 1 (1.5) | 0 |  |
 Others | 1 (1.5) | 0 |  |
Lymph nodal status (%) | Â | Â | 0.271 |
 N0 | 15 (23.0) | 2 (11.7) |  |
 N1 | 22 (33.8) | 4 (23.5) |  |
 N2 | 28 (43.0) | 11 (47.5) |  |
Number of course | Â | Â | 0.119 |
 1/2/3/4 | 2/9/5/49 | 2/0/3/12 |  |
EGFR mutation (%) | Â | Â | 0.626 |
 Negative/unknown | 53 (81.5) | 13 (76.4) |  |
 Positive | 12 (18.4) | 4 (23.5) |  |
ALK fusion (%) | Â | Â | 0.301 |
 Negative/unknown | 64(98.4) | 16(94.1) |  |
 Positive | 1(1.54) | 1(5.8) |  |